PERSPECTA

News from every angle

← Back to headlines

Dyne Therapeutics Stock Rises as Duchenne Therapy Trial Begins

Dyne Therapeutics' stock saw a significant increase following the commencement of a late-stage clinical trial for its Duchenne muscular dystrophy therapy.

20 May, 17:08 — 20 May, 17:08
PostShare

Sources

Showing 1 of 1 sources
seeking-alphaMixed3h ago

Dyne spikes as late-stage trial for Duchenne therapy gets underway

Read full article →

Related Stories

'Astronauts back on Earth': Artemis II crew splashes down after record-breaking moon flyby – video

just now

New Study Explains Tyrannosaurus Rex's Small Forelimbs

43m ago

Mario Tozzi Questions the Myth of Accumulation

1h ago

Over 1,000 New Ocean Species Discovered by Scientists

1h ago